Company
SynAct Pharma AB
Headquarters: Lund, Sweden
Employees: 3
CEO: Mr. Jeppe Ovli Ovlesen EE, MBA
Market Cap
€28.2 Million
EUR as of Jan. 1, 2024
US$31.1 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. It is developing AP1189, a drug candidate for the treatment of arthritis, including psoriatic arthritis. It has a partnership with the University Of àrebro to study the reduction of inflammation in vascular disease. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
SynAct Pharma AB has the following listings and related stock indices.
Stock: FSX: 8F8 wb_incandescent